ArticleClinical research in cardiology : official journal of the German Cardiac Society2026
Differential effects of transcatheter edge-to-edge repair on forward stroke volume in atrial and ventricular secondary mitral regurgitation.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTranscatheter edge-to-edge mitral valve repair (M-TEER) is an established treatment for secondary mitral regurgitation (MR). Forward stroke volume (FSV), reflecting left ventricular forward flow, is a prognostic marker in heart failure and valvular disease. However, its clinical relevance in secondary MR has not been clearly defined.
objectiveTo assess the impact of M-TEER on FSV in atrial and ventricular secondary MR, identify predictors of FSV improvement, and evaluate its association with long-term outcomes.
methodsIn this retrospective single-center study, 103 patients with moderate-to-severe or severe secondary MR (ventricular MR: n = 60, atrial MR: n = 43) underwent M-TEER. FSV was quantified using left ventricular outflow tract measurements before and 4 weeks post-procedure. Clinical outcomes were assessed over a 2-year follow-up period.
resultsProcedural success (MR grade ≤ II) was high (ventricular MR: 95%, atrial MR: 100%). FSV remained unchanged in ventricular MR (49.4 ± 17.3 vs. 49.5 ± 16.5 ml, p = 0.960) but increased significantly in atrial MR (60.5 ± 21.7 vs. 66.8 ± 19.6 ml, p = 0.037). In multivariable analysis, atrial MR etiology (OR 5.12, p = 0.048) and lower baseline FSV (OR 0.36 per 10 ml/m
conclusionM-TEER enhances FSV in atrial but not ventricular secondary MR. Atrial MR etiology and low baseline FSV independently predict FSV improvement. Early FSV improvement does not translate into improved clinical outcomes, suggesting that FSV response reflects hemodynamic adaptation rather than serving as a prognostic marker.
Indexed as
Identifiers
42257863What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.